CUREVAC N.V. 
DGAP-News: CureVac / Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting (English only)
24.06.2021 / 22:15
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
------------------------------------------------------------
CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany / BOSTON, USA - June 24, 2021 - CureVac N.V. (Nasdaq: CVAC),
a global clinical-stage biopharmaceutical company developing a new class of
transformative medicines based on messenger ribonucleic acid ("mRNA"), today
announced the voting results of the Company's annual general meeting.
The shareholders of the Company voted in favour of all proposals, except for
agenda item 13 relating to the authorization of the management board to acquire
shares (or depositary receipts for shares) in the Company's capital. The
proposals voted in favour for included the appointments of Antony Blanc and
Klaus Edvardsen as managing directors, the re-appointment of Pierre Kemula as
managing director and adjustments to the compensation of the supervisory board.
A table containing tabulations of the votes casted is expected to be released
in the coming days.
About CureVac
CureVac is a global biopharmaceutical company in the field of messenger RNA
(mRNA) technology, with more than 20 years of expertise in developing and
optimizing the versatile biological molecule for medical purposes. The
principle of CureVac's proprietary technology is the use of non-chemically
modified mRNA as a data carrier to instruct the human body to produce its own
proteins capable of fighting a broad range of diseases. Based on its
proprietary technology, the Company has built a deep clinical pipeline across
the areas of prophylactic vaccines, cancer therapies, antibody therapies, and
the treatment of rare diseases. CureVac had its initial public offering on the
New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and
employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston,
USA. Further information can be found at www.curevac.com.
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
CureVac Media Contact
Anna Kamilli, Manager Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1684
anna.kamilli@curevac.com
Bettina Jödicke-Braas, Manager Communications
CureVac, Tübingen, Germany
T: 49 7071 9883-1087
bettina.joedicke-braas@curevac.com
Forward-Looking Statements
This press release contains statements that constitute "forward looking
statements" as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the opinions,
expectations, beliefs, plans, objectives, assumptions or projections of CureVac
N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH,
CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the
"company") regarding future events or future results, in contrast with
statements that reflect historical facts. Examples include discussion of the
potential efficacy of the company's vaccine and treatment candidates and the
company's strategies, financing plans, growth opportunities and market growth.
In some cases, you can identify such forward-looking statements by terminology
such as "anticipate," "intend," "believe," "estimate," "plan," "seek,"
"project," or "expect," "may," "will," "would," "could," "potential," "intend,"
or "should," the negative of these terms or similar expressions.
Forward-looking statements are based on management's current beliefs and
assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company's
performance, and you should not place undue reliance on such statements.
Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and
ongoing instability and volatility in the worldwide financial markets, ability
to obtain funding, ability to conduct current and future preclinical studies
and clinical trials, the timing, expense and uncertainty of regulatory
approval, reliance on third parties and collaboration partners, ability to
commercialize products, ability to manufacture any products, possible changes
in current and proposed legislation, regulations and governmental policies,
pressures from increasing competition and consolidation in the company's
industry, the effects of the COVID-19 pandemic on the company's business and
results of operations, ability to manage growth, reliance on key personnel,
reliance on intellectual property protection, ability to provide for patient
safety, and fluctuations of operating results due to the effect of exchange
rates or other factors. Such risks and uncertainties may cause the statements
to be inaccurate and readers are cautioned not to place undue reliance on such
statements. Many of these risks are outside of the company's control and could
cause its actual results to differ materially from those it thought would
occur. The forward-looking statements included in this press release are made
only as of the date hereof. The company does not undertake, and specifically
declines, any obligation to update any such statements or to publicly announce
the results of any revisions to any such statements to reflect future events or
developments, except as required by law.
For further information, please reference the company's reports and documents
filed with the U.S. Securities and Exchange Commission (SEC). You may get these
documents by visiting EDGAR on the SEC website at www.sec.gov.
------------------------------------------------------------
24.06.2021 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt
durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate
News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de
------------------------------------------------------------
Sprache: Deutsch
Unternehmen: CureVac
Friedrich-Miescher-Str. 15
72076 Tübingen
Deutschland
EQS News ID: 1211886
Ende der Mitteilung DGAP News-Service
------------------------------------------------------------
1211886 24.06.2021
